FDA authorizes first robotic exoskeleton for multiple sclerosis

FDA authorizes first robotic exoskeleton for multiple sclerosis

The device will be used to rehabilitate patients with this neurological condition.

Louisa Ochoa

June 14, 2022 | , Reading Time: 2 minutes

A device developed by Acko Bionics Holdings to treat patients with multiple sclerosis. Photo: Acko Bionics Holdings.

United States Food and Drug Administration (FDA) Approved EksoNR Wearable Robotic ExoskeletonFrom Acko Bionics Holdings, for use in 2016 stroke rehabilitation You spinal cord injuries and in 2020 in . for use in acquired brain injuries (ABI).

According to the company, the EksoNR is based on its predecessor, the Ekso GT, and represents a “next generation” motorized lower-body exoskeleton with gait assist. for physical and neurological rehabilitation,

“As a leader Portable Robotic Merchandising Solutions “Treatments for medical rehabilitation, we are committed to maximizing patient access to our technology,” said Steven Sherman, president and CEO of Acko Bionics, in a press release.

“Now expanded to include MS with indications for use, exoNRs have the potential to help significantly more patients and improve patient mobilitySherman said.

“We are excited to see that the device benefits MS patients, Providing critically needed rehabilitation solutionsAs he has done with stroke patients, a Spinal cord injury And an acquired brain injury,” he said.

According to the company, Ekso devices are in use in more than 375 rehabilitation centers around the world and allow patients to almost 200 million steps supporting patients’ hopes for mobility and independence,

Source consulted here.